Successful Drug Discovery

Volume 5
1. Auflage 2021
ISBN: 978-3-527-34754-4
Verlag: Wiley-VCH GmbH

Buch, Englisch, 320 Seiten, Format (B × H): 178 mm x 251 mm, Gewicht: 764 g

In the fifth volume of Successful Drug Discovery, the inventors and primary developers of drugs that made it to the market tell the story of the drug's discovery and development. Case studies of drugs from different therapeutic fields reveal the all-too-often unpredictable path from the first drug candidate molecule to the successfully marketed drug. In addition, this new volume addresses overarching topics for drug discovery, such as drug discovery in academia, and discusses currently important classes of small molecule as well as biological drugs. Comprehensive in scope, the book?s nine chapters provide a representative cross-section of the present-day drug development effort.
 
The authoritative fifth volume is filled with relevant data and chemical information, as well as the insight and experience of the best contemporary drug creators. This important volume:
- Puts the focus on recently introduced drugs that have not yet made it into standard textbooks or general references
- Contains information and insight that is new and often not even available from the primary literature
- Reveals what it takes to successfully develop a drug molecule that has made it all the way to the market
- Is endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC)
 
Written for medicinal chemists, pharmaceutical chemists, organic chemists, Successful Drug Discovery, Volume Five reveals the most recent techniques used by drug innovators in the drug development process.

Autoren/Hrsg.

Fischer, János

Klein, Christian

Childers, Wayne E.

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Naturwissenschaften Chemie Organische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

PART I: GENERAL ASPECTS
Drug Discovery in Academia
From Degraders to Molecular Glues - New Ways of Breaking Down Disease-Associated Proteins
PART II: DRUG CLASS STUDIES
GLP-1 Receptor Agonists for the Treatment of Type-2 Diabetes and Obesity
Recent advances on SGLT2 inhibitors: Synthetic approaches, therapeutic benefits and adverse events
CAR T cells - a Novel Biological Drug Class
CGRP-Inhibitors for the Treatment of Migraine
PART III: CASE STUDIES
Discovery and Development of Emicizumab (HEMLIBRA), a humanized bispecific antibody to coagulation factors IXa and X with a factor VIII cofactor activity
Discovery and Development of Ivosidenib (AG-120; TIBSOVO)
The discovery of Kisqali (ribociclib), a CDK4/6 inhibitor for the treatment of HR positive/HER2 negative advanced breast cancer

Über Autor(innen)

Janos Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. Since 2014 he is Chair of the Subcommittee on Drug Discovery and Development of IUPAC. He received an honorary professorship at the Technical University of Budapest.
 
Christian Klein is Head of Oncology Programs at the Roche Innovation Center Zurich, specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his 15 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of obinutuzumab, the preclinical development of four bispecific antibodies currently in active clinical development, as well as the development of Roche's novel proprietary bispecific antibody platforms e.g. the CrossMAb technology.
 
Wayne Childers is Associate Professor of Pharmaceutical Sciences at Temple University, Philadelphia, USA. He received his academic degrees from Vanderbilt University and from the University of Georgia. He served as an assistant adjunct professor at Bucknell University before accepting a position as a postdoctoral fellow at the Johns Hopkins University School of Medicine. He then joined Wyeth, working in numerous therapeutic areas, including psychiatric diseases, stroke, and Alzheimer's disease, and the treatment of chronic pain. He stayed with Wyeth for 22 years, before joining the faculty of Temple University in 2010.